DM
CPRX icon

Deerfield Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Deerfield Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$97.6M Sell
3,943,600
-967,561
-20% -$23.1M 1.15% 23
2025
Q4 		$115M Sell
4,911,161
-63,606
-1% -$1.42M 1.46% 21
2025
Q3 		$98M Buy
4,974,767
+2,095,291
+73% +$43.1M 1.5% 18
2025
Q2 		$62.5M Sell
2,879,476
-542,673
-16% -$12.8M 1.13% 23
2025
Q1 		$83M Buy
3,422,149
+289,138
+9% +$6.51M 1.64% 20
2024
Q4 		$65.4M Sell
3,133,011
-3,096,623
-50% -$66.5M 1.24% 23
2024
Q3 		$124M Sell
6,229,634
-2,897,671
-32% -$53.7M 1.85% 13
2024
Q2 		$141M Sell
9,127,305
-3,512
-0% -$54.7K 2.35% 9
2024
Q1 		$146M Buy
9,130,817
+241,916
+3% +$3.65M 2.53% 7
2023
Q4 		$149M Buy
8,888,901
+696,901
+9% +$9.53M 2.76% 6
2023
Q3 		$95.8M Hold
8,192,000
– – 2.11% 15
2023
Q2 		$110M Sell
8,192,000
-2,163,099
-21% -$31.1M 2.35% 11
2023
Q1 		$172M Buy
10,355,099
+4,470,651
+76% +$73.8M 3.83% 4
2022
Q4 		$109M Buy
5,884,448
+988,448
+20% +$15.2M 2.27% 11
2022
Q3 		$62.8M Buy
+4,896,000
New +$58M 1.25% 26

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deerfield Management's CPRX Position: Q1 2026 in Review

Deerfield Management reduced its Catalyst Pharmaceutical (CPRX) stake by 20% in Q1 2026, selling an estimated $23.1M and leaving 3,943,600 shares worth $97.6M. The position accounts for 1.15% of the portfolio, ranked #23.

Deerfield Management first reported a position in CPRX in Q3 2022 and has held it in 15 quarters since. The position peaked at $172M in Q1 2023. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Deerfield Management held 3,943,600 shares of Catalyst Pharmaceutical worth $97.6M as of Q1 2026.
  • Deerfield Management sold 967,561 Catalyst Pharmaceutical shares in Q1 2026, an estimated $23.1M.
  • Catalyst Pharmaceutical made up 1.15% of Deerfield Management's portfolio in Q1 2026, its #23 holding.
  • Deerfield Management first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 15 quarters since.
  • Deerfield Management's Catalyst Pharmaceutical position peaked at $172M in Q1 2023.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Deerfield Management's 13F filing for Q1 2026, filed 15 May 2026.